Recent Articles

A Message from Dr. Frank McCormick

| October 7, 2017 | 0 Comments

A Message from Dr. Frank McCormick Frank McCormick, pioneering RAS researcher and former head of the UCSF cancer center, describes the problem with RAS cancers and how the NCI RAS Initiative will attack them.See Original Article What Do We Mean By "RAS Pathway"? Frank McCormick, scientific lead of the RAS Initiative, requests input from the […]

Continue Reading

Study Identifies Crucial Characteristic of High-Risk HPV

| October 5, 2017 | 0 Comments

Study Identifies Crucial Characteristic of High-Risk HPV By comparing the genomes of women infected with a high-risk type of human papillomavirus (HPV), researchers have found that a precise DNA sequence of a viral gene is associated with cervical cancer. See Original Article

Continue Reading

Timing and Sequence Critical for Immunotherapy Combination

| October 3, 2017 | 0 Comments

Timing and Sequence Critical for Immunotherapy Combination When given at the same time, two immune checkpoint inhibitors were ineffective against breast cancer growth in mice, a new study found. The combination was more effective and safer if the two inhibitors were given in a specific sequence.See Original Article

Continue Reading

Kids First Pediatric Research Program Moves Forward

| September 29, 2017 | 0 Comments

Kids First Pediatric Research Program Moves Forward Progress continues to be made with the Gabriella Miller Kids First Research Program, which is creating opportunities for investigators from different research communities to share resources and collaborate on research into childhood cancers and certain birth defects.See Original Article

Continue Reading

Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia

| September 28, 2017 | 0 Comments

Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia FDA has approved gemtuzumab ozogamicin (Mylotarg™) for adults with newly diagnosed CD33-positive AML and patients 2 years and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.See Original Article

Continue Reading

Low-Tech Outreach Methods Improve Colorectal Cancer Screening

| September 26, 2017 | 0 Comments

Low-Tech Outreach Methods Improve Colorectal Cancer Screening Proactive, low-tech outreach approaches can help increase the number of people who get screened for colorectal cancer with a colonoscopy or home stool test and complete the appropriate follow-up.See Original Article

Continue Reading

FDA Expands Approval of Fulvestrant for Advanced Breast Cancer

| September 22, 2017 | 0 Comments

FDA Expands Approval of Fulvestrant for Advanced Breast Cancer FDA has expanded its approval of fulvestrant (Faslodex®) as a standalone treatment for postmenopausal women with advanced HR-positive, HER2-negative breast cancer who have not previously undergone endocrine therapy. See Original Article

Continue Reading

Overcoming the Challenges of Metastatic Cancer: An Interview with Dr. Rosandra Kaplan

| September 20, 2017 | 0 Comments

Overcoming the Challenges of Metastatic Cancer: An Interview with Dr. Rosandra Kaplan NCI’s Dr. Rosandra Kaplan discusses important trends in metastatic cancer research and new ideas for treating and preventing metastatic cancer.See Original Article

Continue Reading

Dr. John M. Carethers to Deliver Second NCI CURE Distinguished Scholars Seminar

| September 19, 2017 | 0 Comments

Dr. John M. Carethers to Deliver Second NCI CURE Distinguished Scholars Seminar On October 5, 2017, Dr. John M. Carethers will deliver the second CURE Distinguished Scholars Seminar. Dr. Carethers will present highlights from his research in hereditary colon cancer, tumor progression, and colorectal cancer disparities. See Original Article

Continue Reading

Long-Term Nerve Damage Possible after Chemotherapy for Breast Cancer

| September 19, 2017 | 0 Comments

Long-Term Nerve Damage Possible after Chemotherapy for Breast Cancer Many women who receive taxane-based chemotherapy to treat breast cancer experience long-term nerve damage, or peripheral neuropathy, data from a large clinical trial show.See Original Article

Continue Reading